Enhanced Cisplatin Cytotoxicity in The Presence of Noscapine in Ovarian Cancer Cell Lines  


Rahbar-Roshandel N, Salehi-Mokani S and Mahmoudian Massoud


Traditional & Complementary Medicine Exhibition 2007 (TCME 2007), Putra World Trade Centre (PWTC), Kuala Lumpur, Malaysia




Cisplatin, cytotoxicity, noscapine, ovarian cancer


Platinum-based chemotherapy is the primary treatment for ovarian cancer and is used currently either alone or in combination with other chemotherapeutic agents. Despite such combination, the majority of patients relapses and become refractory to additional treatment. To overcome this limitation, finding a drug that can enhance cisplatin activity has a special value in the treatment of ovarian cancer. Noscapine a phthalideisoquinoline alkaloid constituting 1-10% of the alkaloid content of opium, has been used as a cough suppressant in humans and in experimental animals. Noscapine also has anti tumor activity, and arrests cells at mitosis, and induces apoptosis in dividing cells. In the present study, we examined the noscapine effects on the cisplatin activity in both cisplatin-sensitive and cisplatin-resistance ovarian carcinoma cell lines. The cytotoxic effects of noscpine were assessed using a tetrazolium-based colorimetric assay (MTT assay) on cisplatin-sensitive and cisplatin­-resistant ovarian cell lines. Noscpaine reduced the EC50 from 400 ng/ml to 75 ng/ml in ovarian cells sensitive to cisplatin and EC50 from 1750 ng/ml to 600 ng/ml in ovarian cells resistant to cisplatin. Noscapine can be used to increase the cytotoxic effects of anticancer drugs like cisplatin.